Corona-Gutiérrez AA, Olivares-Ramírez A, Fajardo-Dueñas S

Language: Spanish
References: 12
Page: 587-592
PDF size: 359.46 Kb.

ABSTRACT

Background: Despite the known benefits of antenatal corticosteroids therapy its use in clinical practice is not generalized.
Objective: To identify factors related to antenatal corticosteroids non administration.
Methods: Cross-sectional and descriptive study that included patients admitted to Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, who had indication for antenatal corticosteroids therapy but did not receive it. Variables: antenatal corticosteroids therapy prescription, factors related to antenatal corticosteroids therapy non administration and lapsed time between diagnosis and birth.
Results: Antenatal corticosteroids therapy were not prescribed in 79 (94%) of 84 patients. Main related factors were imminent birth and severe maternal complication. The longer amount of time from diagnosis to birth was before hospitalization (91 vs 9%, p ‹0.0005).
Conclusion: The biggest and best opportunity for the administration of inducers of fetal lung maturity is during prenatal care, when cases with increased risk of preterm birth are detected.

REFERENCES

1. Howson CP, Kinney MV, Lawn JE. Born too soon: The global action report on preterm birth [Documento en internet]. Suiza: March of Dimes, PMNCH, Save the Children, World Health Organization, 2012 [en línea]. Dirección URL: . (Consulta: 16 diciembre 2013).

2. Hofmeyr GJ. Administración prenatal de corticoesteroides para mujeres con riesgo de parto prematuro: Comentario de la BSR [Documento en internet]. Suiza: Biblioteca de Salud Reproductiva de la Organización Mundial de la Salud, 2009 [en línea]. Dirección URL: . (Consulta: 19 diciembre 2013).

3. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Sys Rev 2006;19(3):CD004454.

4. Royal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality. Guideline no.7. United Kingdom: Royal College of Obstetricians and Gynaecologists, 2004. [En línea]. Dirección URL: mhttp://www.rcog.org.uk/files/rcog-corp/ GTG%207.pdf>. (Consultado 2013 diciembre 19).

5. American College of Obstetricians and Gynecologists. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin no.127: Management of preterm labor. Obstet Gynecol 2012;119(6):1308-17.

6. Centro Nacional de Excelencia Tecnológica en Salud. Diagnóstico y manejo del parto pretérmino. México: Secretaría de Salud, 2009. [en línea]. Dirección URL: . (Consulta: 19 diciembre 2013).

7. Vogel JP, Souza JP, Gülmezoglu AM, Mori R, Lumbiganon P, Qureshi Z y otros. Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. Lancet 2014;384(9957):1869-77.

8. Garay-Cortes MG. Comparación de Curosurf versus Survanta en el tratamiento profiláctico del síndrome de distress respiratorio en el recién nacido pretérmino <32 semanas. Tesis para optar por el grado de Especialista en Neonatología. 2011. Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, México.

9. Leviton LC, Baker S, Hassol A, Goldenberg RL. An exploration of opinion and practice patterns afecting low use of antenatal corticosteroids. Am J Obstet Gynecol 1995;173: 312-6.

10. Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Sys Rev 2011;15(6):CD003935.

11. Erickson K, Schmidt L, Santesso DL, Schulkin J, Gregory K, Hobel C. Obstetricians-gynecologists’ knowledge and training about antenatal corticoids. Obstet Gynecol 2001;97:140-6.

12. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PAC, et al. Why don´t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65.